June 29, 2016: Shire announced positive topline results today from its clinical trial of SHP465-306 in ADHD. The trial looked at 275 adults between the ages of 18 and 55 with ADHD. The study showed both doses of the drug, 12.5mg and 37.5mg, worked better than placebo.
June 29, 2016: The first trial of a CRISPR-Cas9 drug in humans may soon begin, and it isn't being sponsored by a pharmaceutical or biotech company. It's happening through the University of Pennsylvania, funded largely by The Parker Institute—the philanthropy recently created by billionaire Sean Parker.
June 29, 2016: Biotech stocks have been more volatile than usual this year, and it’s unlikely that the recent Brexit, which shook up world markets, is going to help that any. Three well known biotech stocks, bluebird bio, Celldex Therapeutics and Ionis Pharma have all dropped fairly dramatically.
June 29, 2016: Shire cut the ribbon on its new 200,000-square-foot building in Lexington, MA this week. The building, is planned to be the company’s global corporate headquarters.